A company, possibly Scholar Rock, may be affected by a change in its plans, potentially related to a backup plant. The FDA has been issuing warning letters to various companies for manufacturing-related issues, including violations and rejections. It is unclear how these developments will impact Scholar Rock, but its stock has reportedly jumped after resubmitting an FDA filing for a spinal muscular atrophy drug.